Hood S A, O'Brien M, Higgins R
Merrimack Valley Dialysis Metheun, MA, USA.
Nephrol Nurs J. 2000 Feb;27(1):41-2.
The National Kidney Foundation recently published guidelines stating that regular use of intravenous iron therapy will prevent iron deficiency and promote better erythropoiesis than oral iron therapy in patients with end stage renal disease (ESRD) who are undergoing hemodialysis. Although intravenous iron dextran has been shown to be clinically effective in maintaining iron stores in such patients, some clinicians are concerned about the incidence of adverse events associated with this mode of iron supplementation. We conducted a retrospective review of adverse events associated with the use of Dexferrum (American Regent Laboratories, Inc., Shirley, NY) in ESRD patients at an outpatient dialysis clinic. During the 6-month study period, only 1 patient out of 62 (1.6%) experienced adverse events (hypotension, chest pain) related to treatment with Dexferrum. No patients developed anaphylactoid reactions.
美国国家肾脏基金会最近发布了指南，指出对于正在接受血液透析的终末期肾病（ESRD）患者，定期使用静脉铁剂治疗可预防缺铁，并比口服铁剂治疗能促进更好的红细胞生成。尽管已证明静脉注射右旋糖酐铁在维持此类患者的铁储备方面具有临床疗效，但一些临床医生担心这种铁补充方式相关不良事件的发生率。我们对一家门诊透析诊所中ESRD患者使用去铁胺（美国摄政实验室公司，纽约州雪莉）相关的不良事件进行了回顾性研究。在为期6个月的研究期间，62名患者中只有1名（1.6%）经历了与去铁胺治疗相关的不良事件（低血压、胸痛）。没有患者发生类过敏反应。
